
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a clinical-stage biotechnology company that is poised for potential success in the near future due to the expected initiation of its Phase 1b/2a trial for SZN-8141 in DME patients by year-end 2026 and subsequent data catalyst in 2H27. The company also received a positive ruling from the US Patent Trial and Appeal Board, solidifying its intellectual property position. With promising preclinical results and a strategic partnership with Boehringer Ingelheim, Surrozen has the potential to differentiate itself in the competitive Wnt therapeutics landscape and provide value for investors in the long-term.
Bears say
Surrozen is currently a developmental-stage biotechnology company with promising drug candidates in its pipeline, however, the stock faces significant risk factors that could hinder its potential success and achievement of peak commercial revenue estimates. These risks include the possibility of failure in development and commercialization of its products, as well as difficulties in securing necessary capital resources. Additionally, the company's current valuation of $44 per share may not be sustainable if these risks are not mitigated.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares